I

    iBio, Inc. Common Stock (IBIO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.36
    -0.04 (-2.86%)

    Market Cap: $67.56M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    45%(9/20)
    Avg Surprise
    -14.39%

    Upcoming Estimates

    Jun 30, 2026
    EPS Consensus$-0.13
    Range$-0.27 - $-0.05
    7 analysts
    Revenue Consensus
    $64530
    Range$-78330 - $421670
    7 analysts
    Sep 30, 2026
    EPS Consensus$-0.08
    Range$-0.09 - $-0.07
    3 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$-0.08+4.1%
    60d ago$-0.08+3.1%
    30d ago$-0.08+3.1%
    7d ago$-0.08+3.1%
    Current$-0.08
    Revenue Consensus
    $0
    Range$0 - $0
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Sep 26EST
    		-$-0.08---
    Jun 26EST
    		-$-0.13---
    Mar 26
    		$-0.06$-0.06-2.05%Miss+86.8%
    Dec 25
    		$-0.09$-0.06-50.00%Miss+81.3%
    Sep 25
    		$-0.29$-0.43+32.56%Beat+37.0%
    Jun 25
    		$-0.32$-0.36+11.11%Beat+64.5%
    Mar 25
    		$-0.49$-0.32-53.13%Miss+42.6%
    Dec 24
    		$-0.48$-0.46-4.35%Miss+89.2%
    Sep 24
    		$-0.46$-0.46+0.00%Beat-91.9%
    Jun 24
    		$-0.90$-0.47-91.89%Miss+49.9%
    Mar 24
    		$-0.85N/AN/ABeat+92.2%
    Dec 23
    		$-4.42$0.00N/ABeat+79.5%
    Sep 23
    		$-0.24$0.00N/ABeat+99.8%
    Jun 23
    		$-1.80N/A+78.05%Beat+8.2%
    Mar 23
    		$-11.00$-7.20-52.78%Miss+63.3%
    Dec 22
    		$-21.60$-12.50-72.80%Miss+13.6%
    Sep 22
    		$-112.60$-35.00-221.71%Miss-11160.0%
    Jun 22
    		$-1.96$-2.12+7.55%Beat-19700.0%
    Mar 22
    		$-30.00$-27.50-9.09%Miss-50.0%
    Dec 21
    		$-25.00$-20.00-25.00%Miss-25.0%
    Sep 21
    		$-1.00$-1.25+20.00%Beat+90.0%
    Jun 21
    		$0.01N/A+100.05%Beat+116.7%
    Mar 21
    		$-20.00$-20.00+0.00%Beat-2798.6%
    Dec 20
    		$-20.00$-17.50-14.29%Miss-9423.8%
    Sep 20
    		$-10.00N/A+60.00%Beat-4247.8%
    Mar 20
    		$-0.06N/AN/ABeat+72.7%
    Dec 19
    		$-0.69N/AN/ABeat-187.5%
    Sep 19
    		$-0.21N/AN/ABeat+16.0%
    Jun 19
    		$-0.23N/AN/ABeat+39.5%
    Mar 19
    		$-0.22N/AN/ABeat+37.1%
    Dec 18
    		$-0.24N/AN/ABeat+41.5%
    Sep 18
    		$-0.25N/AN/ABeat+40.5%
    Jun 18
    		$-0.38N/AN/ABeat+22.4%
    Mar 18
    		$-0.35N/AN/ABeat+20.5%
    Dec 17
    		$-0.41N/AN/ABeat-13.1%
    Sep 17
    		$-0.42N/AN/ABeat-22.3%
    Jun 17
    		$-0.49N/AN/ABeat-
    Mar 17
    		$-0.44N/AN/ABeat-
    Dec 16
    		$-0.36N/AN/ABeat-
    Sep 16
    		$-0.34N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.78EV/EBITDA-1.59x
    Price/FCF-6.84xFCF Yield-14.63%
    Profitability
    Profit Margin0.00%Operating Margin-9653.00%
    ROE-62.10%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-202.51x
    Current Ratio11.88xQuick Ratio11.88x
    Trading Statistics
    Beta1.31Avg Volume673.69K
    52-Week High$3.8252-Week Low$0.77

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.44
    SMA 20$1.43
    SMA 50$1.49
    SMA 200$1.84
    EMA 10$1.42
    EMA 20$1.43
    EMA 50$1.50
    EMA 200$1.74

    MACD

    Line: -0.02Signal: -0.02Hist: -0.00

    ADX

    ADX: 8.2+DI: 16.3-DI: 25.8

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down12.0
    PSAR$1.54

    Bollinger Bands

    Upper Band$1.50
    Lower Band$1.36
    %B Position959%(Upper)
    Band Width-0.02

    RSI (14-Day)

    Neutral
    40.3

    Momentum Oscillators

    Stoch %K28.3
    Stoch %D41.7
    Williams %R-90.0
    ROC (10d)-4.9%
    Momentum-0.07
    CCI (20d)-152.9
    MFI (14d)26.0

    Volatility Measures

    ATR (14d)$0.08(5.9%)
    StdDev (20d)0.03
    Hist Vol42.1%(High)

    Volume Flow

    VWAP$1.37
    OBV329.4M
    AD Line-255.9M
    CMF (20d)0.041

    Volume Metrics

    Avg Vol (20d)683.5K
    Vol Ratio0.8x
    VWMA (20d)$1.44

    Pivot Points

    R3$1.50
    R2$1.48
    R1$1.44
    Pivot Point$1.42
    S1$1.38
    S2$1.36
    S3$1.32

    Advanced Oscillators

    TSI-7.16
    Ultimate Osc42.6
    KST-15.33

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$0$0$100,000$200,000$0$200,000$0$175,000$0$0$50,000$0
    Cost of Revenue$0$0$0N/A$0$0$0$281,000$0$0$0$31,000
    Gross Profit$0$0$100,000$200,000$0$200,000$0$175,000$0$0$50,000$-31,000
    Operating Expenses$8.37M$9.45M$6.05M$5.40M$4.88M$4.62M$4.11M$3.58M$3.63M$4.50M$5.15M$4.96M
    R&D$3.25M$4.28M$3.55M$3.22M$1.91M$1.88M$1.30M$1.14M$904,000$1.53M$1.61M$2.36M
    SG&A$5.11M$5.17M$2.50M$2.17M$2.97M$2.74M$2.80M$2.44M$2.72M$2.96M$3.55M$2.61M
    Operating Income$-8,365,000$-9,445,000$-5,951,000$-5,198,000$-4,879,000$-4,419,000$-4,106,000$-3,409,000$-3,626,000$-4,496,000$-5,103,000$-4,965,000
    Interest Income$657,000$493,000$267,000$79,000$72,000$112,000$174,000$223,000$43,000$42,000$55,000$50,000
    Interest Expense$22,000$41,000$36,000$44,000$54,000$57,000$57,000$60,000$52,000$34,000$26,000$17,000
    Income Before Tax$-7,730,000$-8,993,000$-5,720,000$-5,163,000$-4,861,000$-4,364,000$-3,989,000$-3,246,000$-2,635,000$-4,488,000$-5,074,000$-4,834,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-7,730,000$-8,993,000$-5,720,000$-5,163,000$-4,861,000$-4,364,000$-3,989,000$-7,778,000$-3,172,000$-8,211,000$-5,746,000$-6,033,000
    EBITDA$-7,930,000$-9,378,000$-5,832,000$-4,913,000$-4,290,000$-4,445,000$-3,828,000$-3,128,000$-2,294,000$-4,147,000$-4,695,000$-5,158,000
    EBIT$-8,365,000$-9,445,000$-5,951,000$-5,198,000$-4,879,000$-4,419,000$-4,106,000$-3,409,000$-2,626,000$-4,496,000$-5,103,000$-4,965,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about IBIO

    News

    iBio (NASDAQ:IBIO) Cut to "Sell" at Wall Street Zen

    Wall Street Zen has downgraded iBio (NASDAQ:IBIO) from a "Hold" to a "Sell" rating, despite a broader analyst consensus remaining "Buy" with an average price target of $5.00. Other firms like Raymond James, Chardan Capital, and B. Riley maintain "Outperform" or "Buy" ratings, while Weiss Ratings reaffirmed a "Sell (D-)" view. iBio shares opened at $1.43, with institutional investors owning approximately 7.9% of the company.

    MarketBeat•8/23/26•
    Somewhat-Bearish

    iBio (NYSE: IBIO) seeks 500M shares, revises equity plan for warrants

    iBio, Inc. (IBIO) is seeking stockholder approval to increase its authorized common shares from 275 million to 500 million and to amend its 2023 Omnibus Incentive Plan's "evergreen" provision. The plan amendment would tie the annual share increase through 2029 to both outstanding common stock and a percentage of shares issuable upon exercise of pre-funded warrants, then revert to a 5% of outstanding common stock formula from 2030-2033. These changes are intended to provide flexibility for future financings, retain talent, and align the equity capacity with the large volume of pre-funded warrants issued in recent financings, while acknowledging potential dilution for existing shareholders.

    Stock Titan•8/20/26•
    Neutral

    iBio (NASDAQ:IBIO) Rating Increased to Hold at Wall Street Zen

    Wall Street Zen has upgraded iBio (NASDAQ:IBIO) from a "sell" to a "hold" rating, though the broader analyst consensus remains a "Buy" with a $5.00 average price target. The company recently reported a quarterly loss of $0.07 per share, missing estimates, and its stock has experienced volatility over the past year. Institutional investors hold approximately 7.9% of iBio's stock.

    MarketBeat•8/15/26•
    Neutral

    Vestal Point Capital (IBIO) discloses 4.0M-share iBio position including warrants

    Vestal Point Capital, LP and Ryan Wilder have reported an updated beneficial ownership of 4,025,000 shares of iBio, Inc. common stock, which includes 1,425,000 shares issuable from warrants. This holding represents a 7.9% stake in iBio, calculated based on 49,678,561 shares outstanding as of May 12, 2026. The filing indicates that all reported shares have shared voting and dispositive power.

    Stock Titan•8/14/26•
    Neutral

    Lynx1 Capital Management (IBIO) corrects 5.4% iBio stake including 2.8M warrant shares

    Lynx1 Capital Management LP and Weston Nichols have filed an amended Schedule 13G for iBio, Inc. (IBIO), correcting their reported beneficial ownership to include 2,807,016 shares of common stock issuable upon exercise of Series F warrants. This represents a 5.4% stake in iBio, based on shares outstanding as of May 12, 2026, and is subject to a 9.99% blocker. The previous filing on February 17, 2026, had inadvertently excluded these warrants.

    Stock Titan•8/14/26•
    Neutral

    Frequently Asked Questions About IBIO

    Does IBIO pay dividends?
    iBio, Inc. Common Stock (IBIO) does not currently pay a regular dividend.
    What is IBIO's market cap?
    iBio, Inc. Common Stock (IBIO) has a market capitalization of $67.56M with a current stock price of $1.36.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In